Core Viewpoint - AgomAb Therapeutics, a Belgium-based biotech company focused on immune and inflammatory diseases, has filed for an IPO to raise up to $100 million [1][2] Group 1: Company Overview - AgomAb Therapeutics specializes in developing innovative disease-modifying therapies for immune and inflammatory diseases [1] - The company was founded in 2017 and is headquartered in Antwerp, Belgium [2] - The lead candidate drug, ontunisertib (AGMB-129), is a selective and potent oral small molecule inhibitor targeting the TGFβR1 pathway, aimed at treating fibrotic diseases [1] Group 2: Product Pipeline - The primary focus is on treating chronic fibrotic diseases by inhibiting the TGFβ signaling pathway [1] - The second clinical-stage candidate, AGMB-447, is an inhaled small molecule inhibitor targeting TGFβR1, under development for idiopathic pulmonary fibrosis (IPF) [1] Group 3: IPO Details - The company plans to list on NASDAQ under the ticker symbol "AGMB" [2] - The IPO's joint bookrunners include JPMorgan, Morgan Stanley, Leerink Partners, and Van Lanschot Kempen [2] - Specific pricing terms for the IPO have not yet been disclosed [2]
比利时免疫炎症生物科技公司AgomAb Therapeutics(AGMB.US)申请在美IPO 拟募资1亿美元
智通财经网·2026-01-19 08:38